“Entyvio” vs. Inflammatory Bowel Disease?
This is VIDEO 1 of 4 from my March 29, 2016 interview with GLOBAL Inflammatory Bowel Disease (IBD) EXPERT, Dr. Mark L. Chapman, from the IBD Center at Mt. Sinai Hospital in New York City. In this video Dr. Chapman explains the science behind how Entyvio works as a Biologic drug to treat Crohn’s Disease and Ulcerative Colitis. More specifically, Dr. Chapman provides the medical explanation for Entyvio being a “lymphocyte trafficking blocker” Biologic, as opposed to the other available IBD Biologic drugs all being anti-TNF activity suppressors. Dr. Chapman also explains how Entyvio evolved as the improved version of the drug, “Tysabri,” which in its former form left IBD patients vulnerable to a dormant, but potentially fatal, brain disease. As the IMPROVED VERSION, Entyvio thankfully no longer presents this horrific risk for IBD patients.
This is VIDEO 2 of 4 from my March 29, 2016 interview with Dr. Mark L. Chapman from the IBD Center at Mt. Sinai Hospital in New York City. In this discussion re: Entyvo, Dr. Chapman goes into detail about WHEN he and his colleagues use Entyvio (and some are even using it as a First Line Biologic for IBD) and HOW they use it in terms of Double Therapies along with immunosuppressant drugs. Dr. Chapman also explains why different doctors utilize different “algorithmic” approaches regarding Biologics and how Health Insurance Companies affect those decisions.
Note: People in Social Media were kind enough to submit questions to me prior to the Interview and Dr. Chapman answered MANY OF THEM. Those Q and As will be in Videos 3 and 4.